High Rates of Dientamoeba fragilis and Blastocystis species in Children's Stool but Minor Clinical Significance.

Blastocystis Dientamoeba diagnostic stewardship microbiome multiplex PCR protists

Journal

The Journal of infection
ISSN: 1532-2742
Titre abrégé: J Infect
Pays: England
ID NLM: 7908424

Informations de publication

Date de publication:
29 Oct 2024
Historique:
received: 16 08 2024
accepted: 25 10 2024
medline: 1 11 2024
pubmed: 1 11 2024
entrez: 31 10 2024
Statut: aheadofprint

Résumé

The aim of this study was to describe the epidemiology and the clinical significance of dientamoeba fragilis (DF) and blastocystis (Bs) in pediatric stool samples. A historical cohort study of children under 18 years of age who underwent stool multiplex PCR for bacteria and parasites. DF and Bs results were not routinely reported. We assessed the frequency of various stool microorganisms and analyzed a composite of symptoms occurring within 14 days before testing and four post-test composite outcomes (symptoms, further medical evaluation, prescriptions of symptomatic treatment or antibiotics). Comparisons were made between children mono-infected with DF or Bs, those with negative PCR results, and those positive for microorganisms with established pathogenicity. Of 36,008 eligible children, 32.5% were positive for DF and 7.9% for Bs. Children positive for DF or Bs did not exhibit higher odds for pre- or post-test composite outcomes compared to those with all-negative PCR results, except for increased rates of abdominal pain and referrals for anti-TTG testing among DF-positive children. Antibiotic prescription was significantly more common among those positive for microorganisms of known pathogenicity. While DF and Bs are frequently detected in pediatric stool samples, their clinical significance appears to be limited.

Identifiants

pubmed: 39481610
pii: S0163-4453(24)00274-3
doi: 10.1016/j.jinf.2024.106340
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106340

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

David Shasha (D)

Head Office, Medical Division, Meuhedet Health Services, Tel Aviv, Israel; Infectious Disease Unit, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: davidsha@tlvmc.gov.il.

Orit Treygerman (O)

Central Laboratory, Meuhedet Health Services, Lod, Israel.

Etti Levy Dahari (EL)

Central Laboratory, Meuhedet Health Services, Lod, Israel.

Efraim Bilavsky (E)

Infectious diseases unit, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.

Dror Hacham (D)

Central Laboratory, Meuhedet Health Services, Lod, Israel.

Daniel Grupel (D)

Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

Yael Paran (Y)

Infectious Disease Unit, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

George Prajgrod (G)

Central Laboratory, Meuhedet Health Services, Lod, Israel.

Galia Zacay (G)

Head Office, Medical Division, Meuhedet Health Services, Tel Aviv, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Classifications MeSH